Because undesirable pharmacokinetics and toxicity are significant reasons for the failure of
drug development in the costly late stage, it has been widely recognized that drug ADMET …

Disregarding the rising alarm on the hazardous nature of various phthalates and their
metabolites, ruthless usage of phthalates as plasticizer in plastics and as additives in …

Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) performed in
animals are often not predictive of drug PKs and PDs in humans, and in vitro PK and PD …

Understanding transporter-mediated drug–drug interactions (DDIs) for investigational
agents is important during drug development to assess DDI liability, its clinical relevance …

Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a
formalized, transparent and quality-controlled way, mechanistic information to apical …

The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic
(PBPK) modeling to individuals in the pharmaceutical industry who may be relatively new to …

The organ-on-a-chip (OoC) paves a way for biomedical applications ranging from preclinical
to clinical translational precision. The current trends in the in vitro modeling is to reduce the …

To estimate human exposure to methylmercury (MeHg), risk assessors often assume 95%–
100% bioavailability in their models. However, recent research suggests that assuming all …

This document was developed to enable greater consistency in the practice, application,
and documentation of Model‐Informed Drug Discovery and Development (MID3) across the …

During the past few decades, the science of toxicology has been undergoing a
transformation from observational to predictive science. New approach methodologies …